1. Renal Cell Carcinoma: Prognostic Factors and Patient Selection
Arie S. Belldegrun 
European Urology Supplements 
Volume 6, Issue 7, Pages (March 2007)
DOI: /j.eursup
Copyright © Terms and Conditions

2. Fig. 1
Disease-specific survival (Kaplan–Meier analysis) of patients with localised (N0M0) or metastatic (N1/N2M0 or any M1) renal cell carcinoma according to UCLA prognostic groups [16]. (Reprinted with permission from the American Society of Clinical Oncology.) (UCLA=University of California, Los Angeles.)
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © Terms and Conditions

3. Fig. 2
External validation of the UCLA UISS prognostic model: Kaplan–Meier survival estimates according to UCLA prognostic groups in 3,120 patients with localised renal cell carcinoma [17]. (Reprinted with permission from the American Society of Clinical Oncology.) (UISS=University of California, Los Angeles (UCLA) Integrated Staging System.)
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © Terms and Conditions

4. Fig. 3
Survival curves (Kaplan–Meier analysis) according to CA IX expression for patients with renal cell carcinoma treated with IL-2 therapy [21]. (Reprinted with permission from the American Association for Cancer Research.) (CA IX=carbonic anhydrase IX; IL-2=interleukin-2.)
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © Terms and Conditions

5. Fig. 4
VEGF-A (panel A), VEGFR-1 (panel B), and VEGFR-2 (panel C) expression in clear cell and papillary renal cell carcinoma [23]. (VEGF=vascular endothelial growth factor; VEGFR=VEGF receptor.)
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © Terms and Conditions